Document Detail


Current status of β-blockers for the treatment of hypertension: an update.
MedLine Citation:
PMID:  22645723     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
β-Adrenoceptor blockers (β-blockers) are one of the oldest classes of cardiovascular drugs still in use. Several short- and long-term clinical outcomes studies have demonstrated their effectiveness and safety for the treatment of hypertension, coronary artery disease, myocardial infarction, heart failure and sudden cardiac death. Due to their safety and efficacy, β-blockers have been recommended by several national and international committees as first-line therapy of hypertension. However, despite their proven benefits, their use as first-line treatment for hypertension has come under criticism lately. Because of these recent developments, several authors have recommended that β-blockers no longer be used as first-line therapy for hypertension. In this review, evidence-based information will be presented, which will demonstrate that β-blockers are an effective and safe class of antihypertensive and cardiovascular drugs for most patients with the exception of black and elderly hypertensive patients in whom the β-blockers are less effective compared to other classes of drugs. In addition, evidence will be presented from several major meta-analyses that β-blockers are equally effective in reducing blood pressure and cardiovascular complications. This review will also discuss differences in the mechanism of action of older and newer (third-generation) β-blockers and provide evidence that newer agents should be preferred over the older ones in the treatment of hypertensive patients with certain comorbidities.
Authors:
S G Chrysant; G S Chrysant
Related Documents :
944573 - Metabolism and structure of the magnesium aspartate-procaine-arrested ischaemic heart o...
8901473 - Relation between energy metabolism, glycolysis, noradrenaline release and duration of i...
188343 - Central antihypertensive effects of inhibitors of the renin-angiotensin system in rats.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  48     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  353-66     Citation Subset:  IM    
Copyright Information:
Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.
Affiliation:
INTEGRIS Baptist Medical Center and the University of Oklahoma, Oklahoma City, Oklahoma, USA. schrysant@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
Next Document:  A report from the American Academy of Dermatology 70th Annual Meeting (March 16-20, 2012 - San Diego...